InvestorsHub Logo
Followers 39
Posts 21536
Boards Moderated 2
Alias Born 07/10/2015

Re: boston745 post# 41584

Monday, 09/16/2024 2:51:31 PM

Monday, September 16, 2024 2:51:31 PM

Post# of 42398

NEW OPPORTUNITIES/MARKETS/PRODUCTS
Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.


All three markets mentioned here from Jan presentation are markets that Solventum sells products in.

I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days


Bryan Hanson & 3M's Solventum

wound care, oral care, health care IT, and biopharma filtration


Quote Source:
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
https://www.3m.com/3M/en_US/medical-us/solutions/catheter-movement/

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.


https://www.mdpi.com/2571-6131/4/2/16/htm


========================================

Section 3 - PioneerPhoenix73 has some misinformation in its post, purposeful or not. Some factual corrections needed in its post:

1. Zimmer Biomet did not acquire Implex as Zimmer Biomet did not exist in 2003. Zimmer acquired Implex 12 years before Zimmer became Zimmer Biomet.
2. Implex material was porous version of tantalum metal it called Hydrocel and Zimmer calls Trabecular Metal. Completely different material and a metal not ceramic.
3. Sintx tech is heavily patented making it very difficult for a partner company to steal its tech. As well as any partnership agreement would likely have extra clauses to prevent such a scenario. The scenario is highly unlikely in Western countries.
4. Sintx is the only company with medical grade Si3n4 with over 100 patents pending worldwide making it unlikely that Zimmer Biomet could license the tech from any other company. Furthermore testing of products related to Sintx and Biomet IP were tested in 2016, & 2018 showing further collaberation well after that 2011 quote. Zimmer Biomet even hired a Si3N4 coatings expert end of 2018 showing continued interest past 2018. Large companies like Zimmer Biomet use small companies like Sintx to de-risk IP and then acquire it. Thats exactly how J&J operates. Does that guarantee anything? No it does not. However according to one scientist, Silicon Nitride is destined to replace current materials used in many fields of medicine.

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

~ Dr Sonny Bal former CEO of Sintx.

In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.


We believe we are the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices used for spinal fusion applications



Quote Sources:

https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm pg 7

Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News